Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer

Hong Jae Chon, Sun Young Rha, Hyung Soon Park, Sang Joon Shin, Hyo Song Kim, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung, Hei Cheul Jeung

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: This phase II trial first describes the combination chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) for pretreated advanced gastric cancer (AGC) patients. Methods: Patients who had previously been treated with greater than or equal to one regimen were enrolled. They received S-1 35 mg/m 2 twice daily on days 1-14 and irinotecan 150 mg/m 2 on days 1 and 15, every 4 weeks. The primary endpoint was overall survival (OS). Results: Among the 38 patients enrolled, 18 patients were treated as second line, and the remaining 20 patients were enrolled as third- or fourth line. A total of 208 cycles were administered with the median being four cycles (range 1-16). The median OS was 8.7 months [95% confidence interval (CI) 7.5-10.3], and the median progression-free survival was 6.3 months (95% CI 5.3-7.3). Low serum albumin (<3.5 mg/dL) was an independent adverse prognosticator for survival. Overall response rate was 17% (95% CI 4-30%). The major grade 3/4 toxicities were neutropenia (26%) and diarrhea (18%). Conclusions: Biweekly IRIS showed the moderate activity as salvage treatment in AGC. Considering high neutropenia and gastrointestinal toxicity, patient selection should be warranted; serum albumin may be a predictive factor for treatment decision.

Original languageEnglish
Pages (from-to)991-999
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume68
Issue number4
DOIs
Publication statusPublished - 2011 Oct 1

Fingerprint

irinotecan
Salvaging
Chemotherapy
Serum Albumin
Stomach Neoplasms
Toxicity
Drug Therapy
Confidence Intervals
Neutropenia
Survival
Salvage Therapy
Combination Drug Therapy
Patient Selection
Disease-Free Survival
Diarrhea

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Chon, Hong Jae ; Rha, Sun Young ; Park, Hyung Soon ; Shin, Sang Joon ; Kim, Hyo Song ; Roh, Jae Kyung ; Noh, Sung Hoon ; Chung, Hyun Cheol ; Jeung, Hei Cheul. / Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 68, No. 4. pp. 991-999.
@article{6d5f0aa34e8e42bba722730b5659f976,
title = "Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer",
abstract = "Purpose: This phase II trial first describes the combination chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) for pretreated advanced gastric cancer (AGC) patients. Methods: Patients who had previously been treated with greater than or equal to one regimen were enrolled. They received S-1 35 mg/m 2 twice daily on days 1-14 and irinotecan 150 mg/m 2 on days 1 and 15, every 4 weeks. The primary endpoint was overall survival (OS). Results: Among the 38 patients enrolled, 18 patients were treated as second line, and the remaining 20 patients were enrolled as third- or fourth line. A total of 208 cycles were administered with the median being four cycles (range 1-16). The median OS was 8.7 months [95{\%} confidence interval (CI) 7.5-10.3], and the median progression-free survival was 6.3 months (95{\%} CI 5.3-7.3). Low serum albumin (<3.5 mg/dL) was an independent adverse prognosticator for survival. Overall response rate was 17{\%} (95{\%} CI 4-30{\%}). The major grade 3/4 toxicities were neutropenia (26{\%}) and diarrhea (18{\%}). Conclusions: Biweekly IRIS showed the moderate activity as salvage treatment in AGC. Considering high neutropenia and gastrointestinal toxicity, patient selection should be warranted; serum albumin may be a predictive factor for treatment decision.",
author = "Chon, {Hong Jae} and Rha, {Sun Young} and Park, {Hyung Soon} and Shin, {Sang Joon} and Kim, {Hyo Song} and Roh, {Jae Kyung} and Noh, {Sung Hoon} and Chung, {Hyun Cheol} and Jeung, {Hei Cheul}",
year = "2011",
month = "10",
day = "1",
doi = "10.1007/s00280-011-1560-9",
language = "English",
volume = "68",
pages = "991--999",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. / Chon, Hong Jae; Rha, Sun Young; Park, Hyung Soon; Shin, Sang Joon; Kim, Hyo Song; Roh, Jae Kyung; Noh, Sung Hoon; Chung, Hyun Cheol; Jeung, Hei Cheul.

In: Cancer Chemotherapy and Pharmacology, Vol. 68, No. 4, 01.10.2011, p. 991-999.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer

AU - Chon, Hong Jae

AU - Rha, Sun Young

AU - Park, Hyung Soon

AU - Shin, Sang Joon

AU - Kim, Hyo Song

AU - Roh, Jae Kyung

AU - Noh, Sung Hoon

AU - Chung, Hyun Cheol

AU - Jeung, Hei Cheul

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Purpose: This phase II trial first describes the combination chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) for pretreated advanced gastric cancer (AGC) patients. Methods: Patients who had previously been treated with greater than or equal to one regimen were enrolled. They received S-1 35 mg/m 2 twice daily on days 1-14 and irinotecan 150 mg/m 2 on days 1 and 15, every 4 weeks. The primary endpoint was overall survival (OS). Results: Among the 38 patients enrolled, 18 patients were treated as second line, and the remaining 20 patients were enrolled as third- or fourth line. A total of 208 cycles were administered with the median being four cycles (range 1-16). The median OS was 8.7 months [95% confidence interval (CI) 7.5-10.3], and the median progression-free survival was 6.3 months (95% CI 5.3-7.3). Low serum albumin (<3.5 mg/dL) was an independent adverse prognosticator for survival. Overall response rate was 17% (95% CI 4-30%). The major grade 3/4 toxicities were neutropenia (26%) and diarrhea (18%). Conclusions: Biweekly IRIS showed the moderate activity as salvage treatment in AGC. Considering high neutropenia and gastrointestinal toxicity, patient selection should be warranted; serum albumin may be a predictive factor for treatment decision.

AB - Purpose: This phase II trial first describes the combination chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) for pretreated advanced gastric cancer (AGC) patients. Methods: Patients who had previously been treated with greater than or equal to one regimen were enrolled. They received S-1 35 mg/m 2 twice daily on days 1-14 and irinotecan 150 mg/m 2 on days 1 and 15, every 4 weeks. The primary endpoint was overall survival (OS). Results: Among the 38 patients enrolled, 18 patients were treated as second line, and the remaining 20 patients were enrolled as third- or fourth line. A total of 208 cycles were administered with the median being four cycles (range 1-16). The median OS was 8.7 months [95% confidence interval (CI) 7.5-10.3], and the median progression-free survival was 6.3 months (95% CI 5.3-7.3). Low serum albumin (<3.5 mg/dL) was an independent adverse prognosticator for survival. Overall response rate was 17% (95% CI 4-30%). The major grade 3/4 toxicities were neutropenia (26%) and diarrhea (18%). Conclusions: Biweekly IRIS showed the moderate activity as salvage treatment in AGC. Considering high neutropenia and gastrointestinal toxicity, patient selection should be warranted; serum albumin may be a predictive factor for treatment decision.

UR - http://www.scopus.com/inward/record.url?scp=80054764357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054764357&partnerID=8YFLogxK

U2 - 10.1007/s00280-011-1560-9

DO - 10.1007/s00280-011-1560-9

M3 - Article

C2 - 21327684

AN - SCOPUS:80054764357

VL - 68

SP - 991

EP - 999

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -